Low-dose hydrocortisone in patients with cirrhosis and septic shock: A randomized controlled trial

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 18, 2010, Pages 1971-1977

  Arabi, Yaseen M ^a   Aljumah, Abdulrahman ^a   Dabbagh, Ousama ^a   Tamim, Hani M ^a   Rishu, Asgar H ^a   Al Abdulkareem, Abdulmajeed ^a   Al Knawy, Bandar ^a   Hajeer, Ali H ^a   Tamimi, Waleed ^a   Cherfan, Antoine ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; HYPERTENSIVE FACTOR; NORADRENALIN; STEROID;

ADRENAL INSUFFICIENCY; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RENAL REPLACEMENT THERAPY; RISK REDUCTION; SEPTIC SHOCK; SHOCK; TREATMENT OUTCOME;

EID: 78650041968     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.090707     Document Type: Article

References (36)

1. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005;53:1-48.
2. Vashist Y, Semela D, Dufour JF. Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases. Med Hypotheses 2004;62:82-5. (Pubitemid 38200010)
3. Newby DE, Hayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but 'splanchnic steal.' QJM 2002;95:827-30.
4. Arkenau HT, Stichtenoth DO, Frolich JC, et al. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol 2002;40:907-13.
5. Gaenzer H, Sturm W, Neumayr G, et al. Hyperdynamic circulation in liver cirrhosis: no evidence for peripheral vasodilation detected by ultrasound of the brachial artery. Am J Gastroenterol 2000;95:551-2.
6. Campillo B, Bories PN, Benvenuti C, et al. Serum and urinary nitrate levels in liver cirrhosis: endotoxemia, renal function and hyperdynamic circulation. J Hepatol 1996;25:707-14.
7. Li CP, Lee FY, Tsai YT, et al. Plasma interleukin-8 levels in patients with post-hepatitic cirrhosis: relationship to severity of liver disease, portal hypertension and hyperdynamic circulation. J Gastroenterol Hepatol 1996;11:635-40.
8. Arabi Y, Ahmed QA, Haddad S, et al. Outcome predictors of cirrhosis patients admitted to the intensive care unit. Eur J Gastroenterol Hepatol 2004;16:333-9.
9. Arabi Y, Haddad S, Goraj R, et al. Assessment of performance of four mortality prediction systems in a Saudi Arabian intensive care unit. Crit Care 2002;6:166-74.
10. Bouachour G, Tirot P, Varache N, et al. Hemodynamic changes in acute adrenal insufficiency. Intensive Care Med 1994;20:138-41.
11. Marik PE, Gayowski T, Starzl TE. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med 2005;33:1254-9.
12. Zietz B, Lock G, Plach B, et al. Dysfunction of the hypothalamic- pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. Eur J Gastroenterol Hepatol 2003;15:495-501. (Pubitemid 36571041)
13. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
14. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine-mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 2000;68:293-303.
15. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supra-physiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50.
16. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyper dynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-32.
17. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
18. Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;141:47-56.
19. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008;36:1937-49.
20. Arabi Y, Alshimemeri A, Taher S. Weekend and weeknight admissions have the same outcome of weekday admissions to an intensive care unit with onsite intensivist coverage. Crit Care Med 2006;34:605-11.
21. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
22. Emori TG, Culver DH, Horan TC, et al. National nosocomial infections surveillance system (NNIS): description of surveillance methods. Am J Infect Control 1991;19:19-35.
23. Lachin JM. A review of methods for futility stopping based on conditional power. Stat Med 2005;24:2747-64.
24. Pocock SJ. Current controversies in data monitoring for clinical trials. Clin Trials 2006;3:513-21.
25. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-303.
26. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8.
27. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
28. Finfer S. Corticosteroids in septic shock. N Engl J Med 2008;358:188-90.
29. Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002;36:395-402.
30. Marik PE. Adrenal-exhaustion syndrome in patients with liver disease. Intensive Care Med 2006;32:275-80.
31. Moran JL, Chapman MJ, O'Fathartaigh MS, et al. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med 1994;20:489-95.
32. Jaattela M, Ilvesmaki V, Voutilainen R, et al. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 1991;128:623-9.
33. Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999;54:861-7.
34. Trevisani F, Bernardi M, De Palma R, et al. Circadian variation in renal sodium and potassium handling in cirrhosis. The role of aldosterone, cortisol, sympathoadrenergic tone, and intratubular factors. Gastroenterology 1989;96:1187-98.
35. Fernandez-Esparrach G, Guevara M, Sort P, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997;26:614-20.
36. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004;350:1629-38.